Endo’s Oxymorphone Solid Tablet Could Be Unscathed By Palladone Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Purdue’s withdrawal of its opiate Palladone may not impact Endo’s pending oxymorphone product because of formulation differences, the company says. Endo hopes to avoid marketing restrictions for oxymorphone based on a broad clinical development program.